CERTARA

Transforming drug discovery and development for good

Rethinking drug discovery and development

Despite numerous advances in science and technology innovation, 90% of therapies that enter clinical trials still fail, leaving patients waiting for treatments and cures.

What if there was a way to identify your "best bets" earlier, optimize resources, and dramatically increase success rates?

There is a better way with integrated in-silico model informed insights

Answering critical questions at every phase can save you years of risk and cost.

Discovery
Identify and prioritize programs and assets with the highest chance of success.

Preclinical
Translate insights to humans faster for better dosing and IND strategies.

Early Clinical
Support first-in-human dose escalation and optimize dose selection and dosing strategy.

Late Clinical
Strengthen regulatory submissions and reduce the need for additional confirmatory studies.

Market Access & Commercial
Communicate value beyond approval with data-driven label expansion, precision dosing, and real-world performance modeling.

Proven and trusted partner

Certara customers have received **90% or more of all novel drug approvals** by the FDA from 2014 through 2024

Greater certainty and success with in-silico approaches

By integrating biosimulation, AI, predictive science and regulatory expertise, Certara eliminates costly missteps and empowers teams to make better decisions, faster. We call it model-informed drug development (MIDD) with a digital-first approach. Our customers see it as a powerful decision-support system.

10+ months
reduced per program[1]

2.5X increase
in success proving proof-of-mechanism with comprehensive modeling package[2]

$5M - $300 Million
potential savings per program[3]



Fig. 1
Certara Model Informed Drug Development (MIDD)

One MIDD platform: Endless opportunities to transform drug discovery and development



Fig. 2 Certara solutions map

1 Sahasrabudhe, Vaishali, et al. "Impact of Model-Informed Drug Development on Drug Development Cycle Times and Clinical Trial Cost." Clinical Pharmacology & Therapeutics, 29 Mar. 2025.
2 Jansson-Löfmark, Rasmus, et al. "Translational PK/PD: A Retrospective Analysis of Performance and Impact from a Drug Portfolio." Drug Discovery Today, July 2025.
3 Based on Certara customer feedback.

Why Certara?

Certara solutions are trusted by top biopharma companies, regulatory agencies, and biotech innovators worldwide.

>100 novel drugs & 325 label claims

were approved by global regulators using Certara technology **in lieu of clinical studies**

25+

virtual patient populations to simulate disease impact

Certara sofware was used in bringing to market:

>100

rare disease treatments

>380

complex biologics programs since 2020

1,500+

experts in 30+ countries, driving innovation

23

Global regulatory agencies adopted Certara software

10+ years

the average tenure for our top 30 customers

2600+

customers in more than **70 countries**

Let's talk

From first-in-human trials to global regulatory approvals and post-launch, Certara solutions can help you move your science forward faster, with confidence. Start transforming your drug discovery and development processes to reduce risk and get more safe and effective medicines to the patients that need them.

Start your transformation

CERTARA